Literature DB >> 19394708

Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

Jamal S Rana1, Maartje E Visser, Benoit J Arsenault, Jean-Pierre Després, Erik S G Stroes, John J P Kastelein, Nicholas J Wareham, S Matthijs Boekholdt, Kay-Tee Khaw.   

Abstract

BACKGROUND: The association of metabolic syndrome and risk of CHD is now well established. The association between 'metabolic dyslipidemia' as defined by high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels and the risk of coronary heart disease (CHD) risk is not known. The aim of this study was to investigate the association between metabolic dyslipidemia, and risk of coronary heart disease (CHD) in apparently healthy men and women.
METHODS: Metabolic dyslipidemia was defined by combination of increased triglyceride (TG) levels (≥150 mg/dl) and low high-density lipoprotein cholesterol (HDL-C) levels (≤50 mg/dl for women and ≤40 mg/dl for men). In the EPIC-Norfolk prospective population study, 21,340 participants without diabetes (9326 men and 12,014 women) were followed for a mean of 11.4 years during which 2075 CHD events occurred. Three multivariate models were used adjusting for other metabolic risk factors including low-density lipoprotein cholesterol (LDL-C).
RESULTS: Compared to men with normal HDL and normal TG, men with metabolic dyslipidemia had an increased risk for CHD (HR 1.61, 95% CI 1.40-1.86). The increased risk remained significant after adjustment for LDL-C and other metabolic risk factors. Among women, metabolic dyslipidemia was associated with increased CHD risk (HR 1.78, 95% CI 1.47-2.15). This association was lost when the model was additionally adjusted for other metabolic syndrome risk factors. In men and women Kaplan-Meier survival curves according to HDL and TG levels revealed that participants with metabolic dyslipidemia had poorer survival compared to people without metabolic dyslipidemia (logrank p<0.001 for each).
CONCLUSIONS: Metabolic dyslipidemia is associated with an increased risk of CHD. This relationship was independent from LDL-C and other risk factors of the metabolic syndrome in men, but not in women. A better management of this phenotype via lifestyle modification or pharmacotherapy may be warranted.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394708     DOI: 10.1016/j.ijcard.2009.03.123

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Role for combination therapy in diabetic dyslipidemia.

Authors:  Haider J Warraich; Nathan D Wong; Jamal S Rana
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

2.  Jujuboside A Ameliorates Myocardial Apoptosis and Inflammation in Rats with Coronary Heart Disease by Inhibiting PPAR-α Signaling Pathway.

Authors:  Chunfang Hu; Zhiyuan Zhang; Guixian Song; Li Zhu; Ruzhu Wang; Zhongbao Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-24       Impact factor: 2.650

Review 3.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

4.  log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.

Authors:  Michel P Hermans; Sylvie A Ahn; Michel F Rousseau
Journal:  Cardiovasc Diabetol       Date:  2010-12-14       Impact factor: 9.951

Review 5.  Effect of pre-diabetes on future risk of stroke: meta-analysis.

Authors:  Meng Lee; Jeffrey L Saver; Keun-Sik Hong; Sarah Song; Kuo-Hsuan Chang; Bruce Ovbiagele
Journal:  BMJ       Date:  2012-06-07

6.  Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study.

Authors:  Jennifer S Lee; Po-Yin Chang; Ying Zhang; Jorge R Kizer; Lyle G Best; Barbara V Howard
Journal:  Diabetes Care       Date:  2017-01-25       Impact factor: 19.112

7.  Contribution of serum lipids as effect modifiers to a relationship between mean arterial pressure and coronary heart disease in Chinese rural population: the Henan Rural Cohort Study.

Authors:  Xia Zhang; Yuqian Li; Yanhua Wang; Kai Hu; Runqi Tu; Haiqing Zhang; Zhongyan Tian; Dou Qiao; Gongyuan Zhang; Chongjian Wang
Journal:  BMJ Open       Date:  2019-11-07       Impact factor: 2.692

8.  Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease.

Authors:  Hong Chang; Qiyan Wang; Tianjiao Shi; Kuiyuan Huo; Chun Li; Qian Zhang; Guoli Wang; Yuanyuan Wang; Binghua Tang; Wei Wang; Yong Wang
Journal:  BMC Complement Altern Med       Date:  2016-03-22       Impact factor: 3.659

9.  The positive association of branched-chain amino acids and metabolic dyslipidemia in Chinese Han population.

Authors:  Panpan Yang; Wen Hu; Zhenzhen Fu; Luning Sun; Ying Zhou; Yingyun Gong; Tao Yang; Hongwen Zhou
Journal:  Lipids Health Dis       Date:  2016-07-25       Impact factor: 3.876

10.  Exposure-weighted scoring for metabolic syndrome and the risk of myocardial infarction and stroke: a nationwide population-based study.

Authors:  Eun Young Lee; Kyungdo Han; Da Hye Kim; Yong-Moon Park; Hyuk-Sang Kwon; Kun-Ho Yoon; Mee Kyoung Kim; Seung-Hwan Lee
Journal:  Cardiovasc Diabetol       Date:  2020-09-29       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.